About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06705608

Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

The goal of this retrospective observational study is to investigate the long-term safety of Fingolimod in individuals with Multiple Sclerosis (MS), specifically focusing on the risk of developing ski...

Lead sponsor: University of British Columbia•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

University of British Columbia

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Identified MS cohort with hospital/physician and prescription claims classified according to the international classification of disease codes and drug identification numbers respectively, using a validated case definition. This case definition requires an individual to have at least three health care encounters (any combination of inpatient encounter, outpatient encounter, or DMT dispensation) for MS in a 1-year window
•MS patients who initiated and used fingolimod, natalizumab, alemtuzumab, dimethyl fumarate, or teriflunomide as monotherapy following MS identification.

Exclusion Criteria

•Pediatric (\<18 years old) MS cases.
•MS cases with less than three years of baseline data before the first drug dispensation.
•MS cases with skin cancer in the three-year baseline period

Related studies

RECRUITINGPhase 3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292 · Multiple Sclerosis

Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis

NCT05748015 · Multiple Sclerosis

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

NCT05047094 · Head and Neck Squamous Cell Carcinoma, Skin Cancer, and more

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

NCT06433765 · Multiple Sclerosis

Sonification Techniques for Gait Training

NCT04876339 · Parkinson Disease, Stroke, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 26, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment4,000

Start dateJan 2003

Last updatedNov 26, 2024

Condition

Multiple Sclerosis Skin Cancer Skin Cancer Melanoma Skin Cancers - Basal Cell Carcinoma Skin Cancer, Squamous Cell+1 more

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 26, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions